by John Conrad | Jun 6, 2024 | NewsBrief
The biopharma sector has undergone significant changes in venture funding and investment trends during the first quarter of 2024, according to a recent PitchBook report. Despite a decrease in deal count, the sector saw an increase in venture funding, with $7.4 billion...
by John Conrad | May 14, 2024 | iBIO News
A new study tackles a burning question: how well do drugs discovered by artificial intelligence fare in clinical trials? With AI making waves in drug discovery, this question is becoming increasingly relevant. The challenge lies in defining what constitutes an...
by John Conrad | Jan 12, 2023 | Member News
In the wake of Evozyne’s hiring of a seasoned tech-company executive as CEO, the Chicago-based biotech company announced it’s developed an AI model that it hopes will revolutionize development of new therapeutic proteins, significantly accelerating the...